Form 4: Cartesian Therapeutics Director Kemal Malik Reports Acquisition of Stock and Options
SEC Form 4 Filing
Director Kemal Malik reports acquisition of common stock and stock options in Cartesian Therapeutics.
Summary
- On January 2, 2025, Kemal Malik, a director of Cartesian Therapeutics, Inc. [RNAC], acquired 2,600 shares of common stock at $0 and 7,800 stock options with an exercise price of $16.93.
- The stock options are exercisable from January 2, 2026, and expire on January 1, 2035.
- Following the transaction, Malik directly owns 8,533 shares of common stock and 7,800 stock options.
- Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2026.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing indicating insider transactions. The acquisition of shares and options could be seen as a mildly positive signal, but it's not definitive.
Positives
- The acquisition of stock and options by a director could be interpreted as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates changes in the holdings of a director at Cartesian Therapeutics.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a company director.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of transaction: Acquisition of common stock and stock options. |
| 01/02/2026 | Stock options become exercisable and Restricted Stock Units vest. |
| 01/01/2035 | Expiration date of the acquired stock options. |
| 01/06/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.